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Abstract
Background: Systemic delivery of anti-sense oligonucleotides to Duchenne muscular dystrophy (DMD) patients to
induce de novo dystrophin protein expression in muscle (exon skipping) is a promising therapy. Treatment with
Phosphorodiamidate morpholino oligomers (PMO) lead to shorter de novo dystrophin protein in both animal models
and DMD boys who otherwise lack dystrophin; however, restoration of dystrophin has been observed to be highly
variable. Understanding the factors causing highly variable induction of dystrophin expression in pre-clinical models
would likely lead to more effective means of exon skipping in both pre-clinical studies and human clinical trials.
Methods: In the present study, we investigated possible factors that might lead to the variable success of exon
skipping using morpholino drugs in the mdx mouse model. We tested whether specific muscle groups or fiber
types showed better success than others and also correlated residual PMO concentration in muscle with the
amount of de novo dystrophin protein 1 month after a single high-dose morpholino injection (800 mg/kg). We
compared the results from six muscle groups using three different methods of dystrophin quantification:
immunostaining, immunoblotting, and mass spectrometry assays.
Results: The triceps muscle showed the greatest degree of rescue (average 38±28 % by immunostaining). All three
dystrophin detection methods were generally concordant for all muscles. We show that dystrophin rescue occurs in a
sporadic patchy pattern with high geographic variability across muscle sections. We did not find a correlation between
residual morpholino drug in muscle tissue and the degree of dystrophin expression.
Conclusions: While we found some evidence of muscle group enhancement and successful rescue, our data also
suggest that other yet-undefined factors may underlie the observed variability in the success of exon skipping. Our
study highlights the challenges associated with quantifying dystrophin in clinical trials where a single small muscle
biopsy is taken from a DMD patient.
Keywords: Duchenne muscular dystrophy, Dystrophin, Exon skipping, Variability, mdx-23
Background
Duchenne muscular dystrophy (DMD) is one of the
most common and severe forms of muscle disease
caused by the loss of the dystrophin protein in patients’
muscles [1–9]. Dystrophin-deficient DMD patients show
a progressive clinical course, with increasing weakness of
the skeletal, cardiac, and respiratory muscles leading to a
loss of ambulation in the second decade and early death
unless ventilation support is introduced [3, 10, 11]. The
most commonly used pharmacological option for DMD
patients is daily high-dose corticosteroid treatment [12, 13].
Although daily glucocorticoids prolong ambulation by
2–3 years, they also cause extensive side effect profiles
that detract from patients’ quality of life [14, 15].
A therapeutic approach currently in multiple clinical
trials in DMD is drug-induced de novo dystrophin
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expression using exon skipping with anti-sense oligo-
nucleotides (AOs) in the muscle of patients [16–23].
This approach partially repairs the patient’s dystrophin
messenger (mRNA) by restoring the triplet codon
reading frame, enabling translation of the patient’s
RNA [20, 24, 25]. Human clinical trial data for exon
skipping in DMD patients remain limited, but the few
muscle biopsy data published thus far show highly variable
dystrophin expression in patients’ muscle samples. Cirak
and colleagues have shown strong immunoblotting
and immunostaining evidence of therapeutic levels of
dystrophin (>10 %) in only one patient out of 12
following systemic exon 51-skipping AO treatment
[20]. Other studies to date have either not reported
dystrophin rescue data [26] or the data were challenging to
interpret [25, 27].
The exon skipping approach has been extensively
studied in pre-clinical models of DMD, including the
mdx mouse model and the canine X-linked muscular
dystrophy (CXMD) model [17, 19, 22, 23, 28, 29]. In the
animal model studies, multiple dosing regimens have
been tested, and several muscles have been studied in
the same treated animal. The results have shown striking
variability in the success of the approach between individual
myofibers in the same muscle, between different muscle
groups in the same animal, and between different animals
receiving the same dosing regimen [18, 21]. These pre-
clinical findings suggest that there are one or more factors
influencing the success of exon skipping, even in adjacent
myofibers. Furthermore, the factors driving this variability
in pre-clinical models may also be important in human
clinical trials, explaining the marked variability in the
limited human patient data presented to date.
Pre-clinical data have shown that there is a strong
dose effect of morpholino chemistry, with high levels
of oligonucleotide drug leading to greater de novo
dystrophin production overall [18]. The most successful
dystrophin replacement in the mdx mouse model has been
seen with intravenous bolus doses of 960 mg/kg [30], and
CXMD dog studies have shown up to 20 % dystrophin
replacement with 200 mg/kg/week delivered intravenously
(three AOs simultaneously) [19]. It has been argued that
the lack of metabolism of morpholino drugs (they are
excreted intact in the urine) and the mechanism of drug
delivery via unstable myofiber membranes lead to dose
equivalency across species boundaries (e.g., murine dose =
human dose) [31]. Most human clinical trials have used
doses up to 50 mg/kg/week, suggesting that human
trials remain at the low end of the doses needed to see
robust de novo dystrophin production. Higher doses
have not been attempted in human clinical trials,
likely because of both the high cost of the morpholino
chemistry [32] and the recommendations of regulatory
agencies, with 10-fold higher concentrations being
required to be tested thoroughly in rodent models for
signs of toxicity.
Understanding the factors that cause the highly variable
de novo dystrophin expression seen in pre-clinical models
would likely lead to more effective means of exon skipping
in both pre-clinical studies and human clinical trials. While
the molecular basis for this variability is still unclear,
we have recently described that muscle inflammation
is linked to the production of TNF-alpha-induced
microRNAs that target the dystrophin mRNA and
could potentially influence the success of exon skip-
ping in DMD [33].
In the present study, we sought to define other possible
factors that might lead to variable success of exon skipping
using morpholino drugs in the mdx mouse model. Here, a
single high bolus of morpholino (800 mg/kg) was ad-
ministered intravenously (IV) in the mdx mouse
model. We compared the results for six different
muscles using three different methods of dystrophin
quantification: immunostaining (or immunofluores-
cent staining), immunoblotting, and mass spectrometry
assays. We then determined whether specific muscle
groups or fiber types showed better success than others
and finally correlated residual drug concentrations in
muscle with the amount of de novo dystrophin protein.
Our data suggest that regardless of the quantification
method utilized for assessment, the muscle group, fiber
type, and residual drug concentration were not well
correlated with de novo dystrophin production. These
results suggest that other factors may be responsible for
the variability observed in the success of exon skipping.
Methods
Animals
All animal procedures were conducted in accordance
with guidelines for the care and use of laboratory ani-
mals as approved by the Institutional Animal Care
and Use Committee (IACUC) of Children’s National
Health System.
The mdx (C57BL/10ScSn-mdx/J) mouse model of
DMD, utilized for all experiments, harbors a nonsense
point mutation in exon 23 of the dystrophin gene and
lacks dystrophin expression in muscle tissue. Four-week-
old male mdx (n = 6) and wild-type (WT) C57BL/10 (n = 2)
mice were purchased from the Jackson Laboratory
(Bar Harbor, ME). All animals were housed at the Chil-
dren’s National Health System (CNHS) Animal Facility in
a vented cage system under 12-h light/dark cycles. Stand-
ard mouse chow and water were provided ad libitum.
Administration of phosphorodiamidate morpholino
oligomer
Mice were anesthetized using 4 % isoflurane and 0.5 L/min
100 % oxygen and then maintained using 2 % isoflurane
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and 0.5 L/min oxygen delivered via a nose cone with a
passive exhaust system on a warming device [34].
The phosphorodiamidate morpholino oligomer (PMO)
mExon 23(+07-18) (5′- GGCCAAACCTCGGCTTACCT-
GAAAT- 3′) against the boundary sequences of exon and
intron 23 of the mouse dystrophin gene was synthesized by
Gene Tools (Philomath, OR, USA). PMO was administered
via a single 800 mg/kg dose through an IV injection via the
retro-orbital sinus as previously described [35]. PMO was
administered in a volume of 300 μl in saline at an injection
rate of 2 μl/s (2 min total injection time). After the
injection, the mouse was placed back into its cage for
recovery and monitored for pain or distress. Control mdx
mice were injected with 300 μl saline exactly as described
for the PMO-treated mice. Uninjected WT C57BL/10 mice
were used as dystrophin-positive controls.
Tissue collection for various quantification methodologies
Mice were sacrificed 1 month after administration of
PMOs. Mice were euthanized via carbon dioxide
inhalation, and multiple muscle tissues were harvested
(tibialis anterior, gastrocnemius, triceps, quadriceps,
heart, and diaphragm) [36]. Muscle tissues were quickly
removed surgically, cut into three parts, snap-frozen in
liquid nitrogen-cooled isopentane, and stored at −80 °C for
further analysis. For immunofluorescent staining, muscles
were placed on cork, coated with OCT mounting medium,
and frozen in liquid nitrogen-cooled isopentane.
Immunofluorescent staining
Dystrophin protein expression
Frozen muscle tissues were sectioned at 10-μm thick and
stored at −20 °C until used. Immunofluorescent (IF) for
dystrophin protein was performed as described previously
[37]. In brief, the muscle sections were brought to room
temperature (RT) but not fixed. For dystrophin staining,
unfixed sections were blocked with 10 % normal sheep
serum, followed by incubation overnight at 4 °C in a
humidified chamber with a P7 dystrophin antibody (1:400;
Fairway Biotech, England). The P7 antibody binds to the
rod domain (exon 57) of the dystrophin protein. Next, the
sections were washed and probed with goat anti-rabbit IgG
Alexa 594 antibody (1:300; Life Technologies, Grand
Island, NY, USA) at RT for 1 h and counterstained with
4′,6-diamidino-2-phenylindole (DAPI) for nuclear staining.
The stained tissue sections were stored at 4 °C for
further imaging and quantification analyses. Staining
was confirmed using alternative dystrophin antibody
(Genetex, Irvine, CA, USA). Images were acquired
using an Olympus BX61 microscope with attached
Olympus DP71 camera module. The surface area of
each section and the relative proportion of the
dystrophin-positive fiber area were determined using
ImageJ software.
Muscle fiber type
Muscle fiber types were identified using the following
antibodies: mouse IgG2b monoclonal anti-type 1 MHC
(clone BA-D5, 1:50), mouse IgG1 monoclonal anti-type
2a MHC (clone SC-71, 1:50), mouse IgM monoclonal
anti-type 2b MHC (clone BF-F3, 1:5), and mouse IgG1
monoclonal anti-embryonic MHC (clone F1.652, 1:25),
all obtained from the Developmental Studies Hybridoma
Bank at the University of Iowa (Ames, IA, USA) [38].
Sections were double-stained with dystrophin antibody
(Genetex).
In brief, serial cross sections (10-μm thick) were fixed in
−20 °C acetone for 10 min. Sections were warmed to RT
for 5 min and then incubated in phosphate-buffered saline
(PBS) for 15 min, followed by a 1-h incubation in PBS with
0.5 % bovine serum albumin (BSA), 0.5 % Triton X-100,
and 1 % horse/goat serum. After three 5-min washes with
PBS, samples were incubated for 2 h with primary antibody.
After three further 5-min washes with PBS with 0.1 %
Tween-20, the samples were incubated for 1.5 h with
secondary antibody at 1:500 dilution: Alexa 488-
conjugated anti-mouse IgG Fc 2b (for type 1 fibers),
Alexa 488-conjugated anti-mouse IgG Fc 1 (for type 2a and
embryonic fibers), and Alexa 488-conjugated anti-mouse
IgM (for type 2b fibers) (Invitrogen, Carlsbad, CA, USA).
Samples were then washed three times for 10 min each,
and the slides were mounted using Prolong Gold with
DAPI (Life Technologies). Images were acquired using the
Olympus BX61 VS virtual slide system (VS120-S5) with
attached Olympus XM10 monochrome camera and
Olympus VS-ASW FL 2.7 software.
Immunoblotting (IB) for dystrophin protein expression
Total protein was extracted from the frozen tissues (tibialis
anterior, gastrocnemius, triceps, quadriceps, heart, and
diaphragm muscles) using radioimmunoprecipitation
assay buffer (RIPA) buffer (50 mm Tris-HCl, pH 8.0, with
150 mm sodium chloride, 1.0 % Igepal CA-630 (Nonidet
P-40), 0.5 % sodium deoxycholate, and 0.1 % sodium
dodecyl sulfate) (Teknova, Hollister, CA, USA) containing
protease inhibitors (Halt protease inhibitor mixture 100X;
Thermo Fisher Scientific, Waltham, MA, USA). Protein
concentrations in the muscle lysates were estimated using
the Bio-Rad Microplate Protein Assay (Bio-Rad, Hercules,
CA, USA) according to the manufacturer’s protocol.
Extracted proteins from mdx-saline (50 μg), mdx-PMO
(50 μg), and C57BL/10 muscles (3.125 μg) were separated
on a Tris-acetate 3–8 % gel (Life Technologies) and
transferred overnight at 4 °C onto nitrocellulose
membranes. Membranes were blocked using 5 % milk
in TBS-Tween (0.1 % Tween) and incubated overnight
at 4 °C with DYS1 and DYS2 monoclonal antibodies
(1:1000; Leica Microsystems, Buffalo Grove, IL, USA).
Membranes were then washed and probed with polyclonal
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rabbit anti-mouse HRP antibody (1:3000; DAKO,
Carpinteria, CA, USA) for 1 h at room temperature. Next,
the membranes were incubated with ECL Western
Blotting Substrate (GE Healthcare, Piscataway, NJ, USA)
and developed on X-ray film (Denville Scientific, South
Planfield, NJ, USA). Similarly, membranes were probed
with anti-vinculin (1:5000; Abcam Inc, Cambridge, MA,
USA) and used as loading controls. Densitometric
quantification of band intensity was measured using
Quantity One software. The band area to be quantified
was determined by identifying the area of the major
dystrophin species band, which was kept constant
between lanes for an individual blot for analysis. Any
possible degradation products were not included in the
quantification, as shown in Additional file 1B.
Dystrophin quantifications in morpholino-treated mdx
muscle were calculated as follows:
percentage of dystrophin expression = (OD from mdx
sample/OD from C57BL/10) × dilution factor = 16 (50 μg
mdx/3.125 μg C57BL/10).
IB runs were performed three times. In the first run,
the same amount of total protein was loaded for the WT
and mdx samples (50 μg). For runs 2 and 3, WT samples
were serially diluted to 3.125 μg total protein for
loading.
Mass spectrometry for dystrophin protein expression
Dystrophin protein levels for the tibialis anterior,
gastrocnemius, and triceps muscles were determined
using MS for PMO-treated mdx mice (n = 6) in
comparison to a C57BL/10 control, as described
previously [39]. Using the same protein extracts as
for the immunoblots, 50 μg of total protein for each
muscle was mixed with 25 μg of an internal standard
for stable isotope labeling of amino acid in mammals
(SILAM) that had been extracted in the same RIPA
buffer from a gastrocnemius muscle [40, 41]. A SILAM
mouse is a C57BL/6J mouse fully labeled with 13C6-lysine,
so that all lysine residues are 6 Da heavier [39, 40]. Un-
labeled and labeled protein mixtures were separated by 1D
electrophoresis. The region corresponding to approximately
300–500 kDa was excised and in gel-digested with trypsin.
The resulting peptides were dried by vacuum centrifugation
and resuspended in 20 μl of HPLC-grade water with 0.1 %
formic acid and 2 % acetonitrile (buffer A). Each sample
(5 μl) was injected onto a NanoEasy HPLC and loaded
and equilibrated in Buffer A at 800 Bar onto an
EasySpray C18 50 μm column, followed by a gradient
of 0–35 % acetonitrile at 300 nL/min over 24 min, and
coupled online to a Q Exactive mass spectrometer
(ThermoFisher, San Jose, CA). The Q Exactive was
operated in timed targeted MS2 mode for 13 unlabeled and
labeled peptides with the following parameters: positive
polarity; resolution 17,500; AGC 1e6; max IT 60 ms; MSX
count 4; isolation width 2 m/z; first m/z 150; and NCE 27.
Timed targeted mass spectral data were analyzed using
Skyline, version 2.6.0.6709 (skyline.gs.washington.edu) to
determine the ratio of unlabeled to labeled for each
transition for each peptide. A total of 13 dystrophin
peptides and 3 filamin C peptides with four to seven y-ion
transitions each were monitored. Peptides with poor co-
elution transitions were removed (Skyline “Peptide Peak
Found Ratio” score <0.9). Peptide ratios were averaged to
give the mean protein ratio. The dystrophin ratio was
compared to the filamin C ratio for each sample. PMO-
treated samples were compared to the corresponding
C57BL/10 muscle to determine the percentage of normal.
ELISA for PMO quantification in muscle lysates
Protein lysates from the previous dystrophin quantifica-
tion experiments by IB and MS were used for PMO
quantification by a high-sensitivity hybridization ELISA,
as previously described [42]. In brief, sample lysates were
diluted 1/20, 1/200, and 1/2000 in a control muscle lys-
ate buffer (0.2ug/μL protein), and PMO standards were
diluted to various concentrations in a similar manner.
Hybridization was facilitated using an anti-sense probe to
the PMO with both a biotin epitope and a DIG tag for
hybridization and carried out at 37 °C. After hybridization,
100 μL of the hybridization mix was pipetted into duplicate
wells on avidin-coated plates and incubated at 37 °C for
30 min. The plates were then washed, and each well was
treated with micrococcal nuclease (NEB, M02475), followed
by incubation with an anti-digoxigenin-AP Fab fragment
antibody (Roche, 11093274910). Lastly, AttoPhos Substrate
(Promega, S101C) was added to the plates and incubated at
37 °C for 30 min. Fluorescent readings were obtained, and
PMO concentrations were quantified and calculated on the
basis of the PMO standard curve.
Statistical analysis
All data are presented as dystrophin percent of C57BL/10
(normal) and means ± standard deviation of the mean.
Correlation analysis between quantification methods was
performed to determine Spearman’s statistical correlations.
p < 0.05 was considered significant.
Results
Dystrophin rescue is highly variable after a single 800 mg/kg
IV injection
In order to fully characterize the level of dystrophin
restored by exon skipping 1 month after a single high-
dose PMO injection in mdx mice, we analyzed six
different muscles from six animals by immunofluorescent
(IF) staining and immunoblotting (IB). Also, the protein
extracts that were prepared for IB from three muscles
were analyzed using a quantitative mass spectrometry
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(MS) stable isotope spike-in approach. For each muscle,
dystrophin expression was calculated as a percentage of
normal as compared to C57BL/10 dystrophin protein
levels. Table 1 shows the average dystrophin protein
expression determined for each muscle group across all
animals and the standard deviation for all three quantifica-
tion methods. Expression levels of de novo dystrophin
varied highly between animals and between muscles,
regardless of the detection method used, ranging from
essentially zero dystrophin up to 80 % of wild-type control
levels (see Additional file 2 for individual values).
Dystrophin protein was visualized by IF using anti-P7
antibody (Fig. 1a). A single high dose of PMO resulted
in dystrophin localization to the membrane, which was
detected with high geographic variability across the
section (Fig. 1b, c). We found dystrophin-positive fibers
to be clustered in groups throughout the section area,
with positive and negative fibers interspersed (Fig. 1e).
Muscle sections with low numbers of dystrophin-positive
fibers, such as the quadriceps, also showed positive fibers
isolated in small clusters, with the majority of the section
area showing dystrophin-negative fibers (Fig. 1c).
The triceps muscle showed the highest dystrophin
rescue levels, at an average of 38 % of normal (range 9
to 78 %, n = 6). We did not observe significant
dystrophin-positive staining in cardiac muscle, other than
sporadic positive fibers that may have been revertants
(Fig. 1c). The other muscles evaluated averaged ~10 % of
wild-type dystrophin levels (Fig. 1d).
The tibialis anterior muscle showed the highest level
of variability among the six mice tested, with an average
(mean ± SD) of 8.7 % ±8.91 % (a relative standard
deviation of 102 %). The lowest variability was observed
in the diaphragm muscle, with an average dystrophin
level of 10.68 % ±5.41 % (a relative standard deviation
of 50 %) (Table 1).
IB was carried out on muscle homogenate protein
extracts to further quantify total dystrophin as a percentage
of wild-type levels. Table 1 shows the average expression of
dystrophin for each muscle analyzed, and Additional file 2
lists the individual sample values. Consistent with our IF
results, IB-quantified dystrophin protein levels were highly
variable between animals and muscle groups (Fig. 2a). We
again observed dystrophin rescue to be the highest in the
triceps (average 27 %, range 11 to 71 %) and the lowest in
the quadriceps (average 2.5 %, range 1 to 9 %) (Fig. 2a, b).
Notably, we found low levels of dystrophin protein in
cardiac muscle 1 month after high-dose PMO injection
(Table 1 and Fig. 2). Again, the tibialis anterior muscle
showed the highest level of variability among the mice
tested, with an average dystrophin level of 9.18 ± 12.88 %
(a relative standard deviation of 140 %) (Table 1). It is
important to note that the quantification dystrophin
immunoblotting can be challenging due to potential
proteolytic degradation of samples (Additional file 1B).
We have recently reported on a mass spectrometry (MS)
method to quantify dystrophin using stable isotope-labeled
dystrophin peptides [39]. We performed quantitative MS
on a subset of muscle protein homogenates that were used
for IB. Dystrophin protein levels as quantified by MS
were variable between the triceps, gastrocnemius, and
tibialis anterior, consistent with previous results
(Fig. 3). The triceps showed the highest average
dystrophin expression (average 23 %, range 6 to 83 %).
The tibialis anterior and gastrocnemius had lower
levels (average 9 and 3 %, respectively), as shown in
Table 1. The standard deviation range for MS also
showed that dystrophin expression was highly variable
between mice for a given muscle group (Table 1).
The results from all three quantification methods
showed that dystrophin rescue was highly variable between
animals and between the muscles tested; however, the
triceps demonstrated the highest dystrophin expression
levels overall (Table 1).
Variation in de novo dystrophin restoration is independent
of muscle/fiber type
Whole-muscle studies have indicated that adaptive
changes in protein synthesis can occur in a myofiber
type-dependent manner [43, 44]. To explore potential
myofiber type differences in the rescue levels of the
dystrophin protein, we compared muscles composed
predominantly of fast-twitch fibers (EDL) to those
Table 1 Dystrophin quantification (% relative to WT)
Muscle Immunofluorescence Immunoblotting Mass spectrometry
Mean ± S.D. RSD % Mean ± S.D. RSD % Mean ± S.D. RSD %
Triceps 38.54 ± 27.45 71.0 27.19 ± 29.56 108.7 22.85 ± 29.69 130.0
Quadriceps 10.81 ± 10.64 98.3 2.46 ± 2.03 82.7 – –
Diaphragm 10.6 ± 5.41 50.7 14.54 ± 10.40 71.6 – –
Gastrocnemius 10.42 ± 7.87 75.5 8.36 ± 9.54 114.1 2.75 ± 2.40 87.1
Tibialis Anterior 8.70 ± 8.91 102.4 9.18 ± 12.88 140.3 9.12 ± 9.09 99.6
Heart 0.24 ± 0.22 93.2 0.49 ± 0.02 5.1 – –
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composed of predominantly slow-twitch muscle (soleus)
and also to muscles of mixed myofiber type (triceps).
We first blotted whole-muscle extracts to detect any
potential preference of particular muscle types for
dystrophin restoration upon exon skipping (Fig. 4a, b). By
IB, we did not find any significant preferences in
dystrophin restoration between the soleus (slow-twitch
muscle) and EDL, a 100 % fast-twitch muscle. In fact, we
observed the same variability pattern described above. For
the soleus, one mouse (mdx-1) of the five tested showed
very high dystrophin rescue, but low levels (or no protein)
were detected in the other animals (Fig. 4a). For the EDL,
low dystrophin levels were detected in all the mice but in
variable amounts (Fig. 4b).
Although we saw no difference in the variability of
dystrophin rescue between fast and slow muscles, we
asked whether there might be a fiber-type preference for
dystrophin rescue in the triceps, which contains mixed
fiber populations. By IF, we identified four different fiber
types (slow-twitch type 1, fast-twitch types 2a and 2b,
Fig. 1 Variability of dystrophin protein expression, as shown by IF after PMO injection. a Representative images of C57BL/10 (WT) and b PMO-treated mdx
tibialis anterior sections stained for dystrophin. The WT control shows uniform IF staining for dystrophin. Insert at ×40 shows expected staining
pattern for dystrophin-positive fibers. b PMO-treated mdx tibialis anterior shows a mosaic staining pattern and clustering of positive fibers.
The yellow line represents the border between the tibialis anterior and EDL. Quantification was performed on the entire area of the muscle
section. c Representative images of mouse mdx-6 showing variability between the muscles of the same animal. Images were selected
to show positive fiber clustering and do not represent total area quantification. d IF quantification of diaphragm, gastrocnemius, heart,
quadriceps, tibialis anterior, and triceps for all mice (n= 6). e Geographic variability observed within the highly rescued triceps from mouse mdx-1. All
tissues were sectioned (10-μm thick), stained, and probed with goat anti-rabbit IgG Alexa 594 antibody. Dystrophin-positive fibers were normalized to the
area of the muscle section and the WT percentage of positive fibers. Original magnification for a, b, e=×20; scale bar, 500 μm; for c=×40; scale bar, 100 μm
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and embryonic) and co-stained for dystrophin. We did
not observe dystrophin rescue to be confined to a
particular fiber type, since dystrophin-positive staining
was seen in both the slow and fast fiber types in the
triceps (Fig. 4c). The triceps contains a high proportion of
type 2b fibers, with type 1 and type 2a fibers distributed in
specific areas of the muscle. As demonstrated in Fig. 1, the
dystrophin-positive fibers were clustered and geographically
dispersed; large dystrophin-positive clusters were observed
within regions rich in both slow (type 1)- and fast (type 2a
and 2b)-twitch myofibers, suggesting that there is no fiber-
type preference with regard to the efficiency of dystrophin
rescue in the triceps (Additional file 3). We also saw a
number of small regenerating fibers that were positive for
the embryonic myosin heavy chain isoform, but we did not
see any dystrophin expression in these fibers (Fig. 4c and
Additional file 3). This result presumably reflects the fact
that the new fibers were formed during the time period
when PMO was no longer present.
Dystrophin rescue does not correlate with residual
morpholino concentration in tissue
To determine whether dystrophin rescue was correlated
with residual morpholino in muscle, we measured
PMO concentrations in the muscle lysate samples used
for quantification of dystrophin by IB and MS. We
hypothesized that highly rescued muscles would show
better uptake and retention of PMO at 30 days after
Fig. 2 Dystrophin protein expression as detected by IB 1 month
after PMO injection. a IB of protein lysates from diaphragm, heart,
gastrocnemius, quadriceps, tibialis anterior, and triceps in PMO-treated
mdx mice (n= 6) vs. WT control shows variability of dystrophin expression
between muscles in PMO-injected mdx mice. There is variation in the
same muscles between different mice (across) and different muscles in
the same individual mouse (down). WT samples were serially diluted to
3.125 μg for protein loading. Vinculin (117 kDa) was used as a loading
control. Densitometric analysis was performed using Quantity One
software. b Dystrophin quantification by IB, demonstrating the percentage
dystrophin expression in PMO-injected mice vs. WT (set to 100 %). Plots
show high variability between mice within a muscle group and between
muscles. All the data are presented as mean percentages
Fig. 3 Dystrophin protein expression as detected by MS. a Triceps,
tibialis anterior, and gastrocnemius RIPA buffer extracts were analyzed by
MS. The percentage of dystrophin protein expression in PMO-injected
mdx mice was compared to the dystrophin percentage in WT. All data
are presented as mean percentages
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delivery. To investigate drug retention, morpholino
concentrations were determined by a recently described
high-sensitivity ELISA assay, which has a lower detection
limit of 5 pM [42].
After 30 days, we observed that residual PMO concentra-
tions varied greatly among the muscles (Additional file 4)
but saw no correlation between PMO concentration
and de novo dystrophin levels after exon skipping,
except for one outlier (Fig. 5). The high-responder
mouse that showed over 80 % dystrophin rescue in the
triceps by both IB and MS (mdx-1) showed a positive
correlation with PMO retention at 1214.6 pM (Table 2).
This data point skewed the correlation toward a posi-
tive trend and was then removed from further analysis
(data not shown); without this sample, no significant
correlation was found between residual PMO and dys-
trophin expression rescue (Fig. 5). Among all the mus-
cles evaluated, the diaphragm showed the highest
residual PMO concentration (822 pM ± 341 pM), and
the tibialis anterior showed the lowest (49.6 ± 39.9 pM)
(Table 2).
In addition, we also measured residual PMO
concentrations at different time points to monitor PMO
pharmacokinetics in muscle after a single high dose.
Two additional groups (n = 3) were treated with PMO
and sacrificed 2 and 7 days after delivery of a single
high-bolus IV dose. We assessed PMO levels as a func-
tion of time in the triceps and gastrocnemius. The high-
est levels of PMO in muscle were quantified 2 days after
PMO administration for both muscle groups. Subse-
quently, PMO levels decreased as a function of time
(Fig. 6). Two days after PMO delivery, no dystrophin pro-
tein was detected by IB or IF (data not shown). On day 7,
dystrophin protein was quantified at low levels by both IF
and IB (Additional file 5). Our data suggest that dys-
trophin levels are detectable within a week of morpholino
delivery and reach higher levels at day 30, although re-
sidual PMO concentrations are declining at that point.
Fig. 4 De novo dystrophin restoration varies independently of muscle/fiber type. a IB of the predominately slow-twitch muscle soleus and b fast-
twitch EDL muscle shows no preference for dystrophin rescue by muscle fiber type. WT samples were loaded at 25 μg, and vinculin was used as a
loading control. For mdx mice, 75 μg of total protein was loaded. c IF in serial sections from the triceps muscle that showed the highest dystrophin
rescue for fiber-type identification of type 1, type 2a, type 2b, and embryonic myosin heavy chain (eMHC) isoforms (green) and dystrophin (red).
Asterisks and pound signs indicate the same muscle fiber in different images. Original magnification for a = ×40; scale bar, 100 μm
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Discussion
Systemic delivery of AOs to dystrophin-deficient muscle is
known to be dose-dependent, but variable effectiveness has
been achieved in dystrophin correction (in mice, dogs, and
humans). This variability in biochemical efficacy is generally
seen between individual myofibers in the same muscle
sample, as well as between different muscle groups (tested
in dog and mouse), and between different individuals
tested. We sought to test a number of variables that might
underlie this variation, including residual drug in tissues
(e.g., more residual drug may indicate greater success) and
different muscle groups. An additional factor contributing
to variability in the apparent success of exon skipping is the
use of different methods to measure dystrophin. Both IF
and IB have relatively low reliability in terms of quantifying
low-abundance proteins, which presents a considerable
problem in the context of exon skipping, for which only
low dystrophin levels have been achieved with the current
AOs in clinical trials (poor coefficients of variance (CVs)).
Thus, the variability reported in exon skipping could be a
consequence of unreliability in the quantification method.
Here, we compared IF, IB, and stable isotope MS methods
in the same samples. We found that all three dystrophin
Fig. 5 Correlation between residual PMO in muscle and de novo
dystrophin. a–c Percentage of WT dystrophin as measured by a
IF, and PMO levels measured by hybridization ELISA were plotted with
a regression line. The same analysis was performed for dystrophin
quantified by b IB and c MS. There was no significant correlation, as
illustrated by the regression lines. Note that for MS we have fewer data
points because we measured only three muscle groups by this
method (N = 18)
Table 2 Residual morpholino concentration 30 days after PMO
administration
PMO conc (pM/ug protein)
ID Tricep Quad Dia Gas TA Heart
mdx-1 1214.6 380.2 822.1 289.9 76.2 171.0
mdx-2 109.1 97.7 606.1 201.2 20.2 46.3
mdx-3 45.8 154.1 42.6 82.9 113.3 77.1
mdx-4 60.1 45.2 40.1 83.8 25.0 33.4
mdx-5 26.2 42.7 130.4 106.7 8.4 45.1
mdx-6 38.8 43.4 65.3 137.4 54.5 136.6
Average 249.1 127.2 284.4 150.3 49.6 84.9
SD 473.9 131.5 341.3 81.4 39.9 56.3
Fig. 6 Time course of residual PMO concentration. a Residual
morpholino concentration was measured in the triceps and
gastrocnemius muscle extracts at 2 (n= 3), 7 (n= 3), and 30 (n= 6) days
after PMO administration. No statistically significant differences were
found between the concentrations of PMO in the two muscle groups
for a given time point. We observed a decline in the PMO concentration
in muscle over time
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testing methods provided similar qualitative results, with a
strongly positive muscle by one method also being strongly
positive by the other two methods. Poor coefficients of vari-
ance were observed in muscles that had lower dystrophin
rescue levels, highlighting the challenge of attempting to
quantify low levels of dystrophin (Additional file 2). We
also found a correlation between the transcript levels by
real-time quantitative PCR (qPCR) and the dystrophin
protein amounts in tibialis anterior muscle from the tested
mice (Additional file 6).
We delivered a single high-dose IV injection (800 mg/kg)
and examined muscles after 1 month. It is well established
that repeated injections (generally weekly) increase the
success of exon skipping; however, we felt that a single
high-dose injection was technically more feasible and less
variable, allowing for better interpretation of the results.
Our data were consistent with previous reports, in which
the amount of drug-induced dystrophin production was
highly variable [18, 21]. We showed that the triceps muscle
had the greatest degree of rescue (6–83 %), whereas other
muscle groups showed generally lower rescue (3–9 %).
Despite considerable investigation, the molecular basis
for variability in the level of dystrophin expression
induced by AOs is still unclear. The extent of dystrophin
rescue does not appear to be influenced by fiber type,
since similar expression patterns were seen in fast and
slow muscles, and no preference for individual fiber type
was observed within muscles with mixed fiber types. It is
attractive to hypothesize that variability in dystrophin
rescue is driven by success in drug delivery to that muscle,
and this relationship may be reflected in the preferential
retention of the AO drug in the most highly rescued
muscles. However, we saw no correlation between residual
morpholino concentration and dystrophin content as
measured by IF, IB, or MS. This analysis does not rule out
the possibility that highly expressing muscles may have had
greater initial delivery of morpholino at the time of injec-
tion, may have restored the dystrophin, and then
subsequently lost the morpholino.
To begin to test this possibility, we compared the
morpholino content of triceps (generally high dystrophin
rescue) and gastrocnemius (generally low dystrophin
rescue) at 2 and 7 days after injection. There were no
significant differences in the morpholino content of the
triceps and gastrocnemius at any time point, arguing
against morpholino delivery and/or retention as a major
factor driving the success of the dystrophin rescue. IV
injections were delivered via the retro-orbital sinus, and
it is possible that the triceps received the highest dose of
morpholino because of its relative proximity to the
orbital sinus; however, the lack of correlation with tissue
morpholino concentration at 2 days post-injection would
seem to argue against this explanation. Other factors not
investigated here could have influenced the higher
dystrophin rescue in the triceps, such as muscle activity
and/or muscle regeneration.
Given that neither muscle fiber type nor residual drug
levels appeared to have a significant effect on the variability
seen in dystrophin expression, we must speculate on the
other variables that could contribute to the success of exon
skipping that were not examined in the present study. It is
evident from all of the muscles studied that
dystrophin rescue occurs in a patchwork fashion,
with dystrophin-positive fibers occurring in large
clusters in geographically distinct regions rather than
being randomly distributed throughout the muscle
cross section. This pattern is interesting in the
context of DMD pathology, which is characterized
by specific regions of inflammation, degeneration,
and regeneration within the muscle. Hence, drug
uptake and subsequent dystrophin expression may be
influenced by the microenvironment surrounding
each individual fiber.
The variable histopathology associated with DMD is
thought to arise as a result of asynchronous regeneration,
which creates muscle microenvironments with varying
degrees of pro-inflammatory and pro-fibrotic signaling [45].
A recent study by our group showed that muscle
inflammation is linked to the production of TNF-
alpha-induced microRNAs that target the dystrophin
mRNA and inhibit dystrophin translation in Becker
muscular dystrophy patients [33]. We have demon-
strated an inverse correlation between the expression
of dystrophin-targeting microRNAs and dystrophin
rescue following AO administration to mdx muscles,
highlighting the potential for these microRNAs to
influence the success of exon skipping in DMD.
Hence, we believe that the inflammatory muscle
microenvironment is likely to be at least partially
responsible for the “patchwork” pattern of variability
in the AO-induced dystrophin rescue we report here.
Finally, based on these findings, it appears that co-
administration of compounds such as prednisone to
inhibit the miRNA-inducing aspect of inflammation,
together with AOs, has considerable potential as a
strategy for both improving the level of dystrophin
rescue and for decreasing inter-patient variability in
future clinical trials of these exon skipping drugs.
Conclusions
Variation in the level of dystrophin expression induced
by AOs remains a major problem in human trials. Here,
we show that dystrophin rescue occurs in a sporadic
patchy pattern which, interestingly, reflects the patchy
nature of DMD/mdx pathology, characterized by
discrete regions of inflammation, degeneration, and re-
generation within a muscle. Our data from the mdx
mouse demonstrate no correlation, at the microscopic
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level, of dystrophin induction by this means with indi-
vidual anatomical muscle or with fiber types within
muscle. Nor is there any correlation between residual
drug concentration and dystrophin induction within
whole muscles. We suggest therefore that other factors
may play important parts success of exon skipping.
This highlights the challenges associated with quanti-
fying dystrophin in clinical trials where the single small
muscle biopsy taken from a DMD patient is unlikely to
be representative of the whole musculature over which
any therapeutic effect is distributed. Thus, while dys-
trophin quantification is an important part of assess-
ment, the large inter-sample variability should be taken
into consideration when interpreting the data in human
clinical trials.
Additional files
Additional file 1: Proteolysis in dystrophin immunoblotting and
band quantification. A) Dystrophin immunoblotting of six muscles
(triceps, quadriceps, diaphragm, gastrocnemius, tibialis anterior, and
heart). The panel shows the entire blot area of the cropped images
shown in Fig. 2a. Mouse ear-tag IDs are shown on the gastrocnemius
blot. B) For dystrophin band quantification, x-ray films were scanned, and
densitometry analysis was carried out using a Bio-Rad GS-800 calibrated
densitometer and Quantity One software. Band area to be quantified was
determined by delineating the largest band, which was kept constant for
quantification of all other lanes. Degradation products were not included
in the quantification as shown. (PDF 128 kb)
Additional file 2: Intra-sample variability—dystrophin protein
(% relative to WT). The table provides individual values for dystrophin
quantification by IF and IB. Expression levels of de novo dystrophin
varied highly between animals and between muscles, regardless of the
detection method used. (PDF 365 kb)
Additional file 3: Dystrophin rescue is not preferential to a
particular myofiber type. IF in serial sections were stained for fiber-type
identification of type 1, type 2a, type 2b, and embryonic myosin heavy
chain isoforms (green) and dystrophin (red). Top panel from triceps
muscle with the highest level of dystrophin rescue at 78 % (mdx-1)
shows no myofiber type 1 double staining, some type 2a, and most type
2b positive for dystrophin. Bottom panel is a triceps with lower
dystrophin rescue at 27 % (mdx-3) showing the opposite distribution of
double stain. Here, exon skipping took place in regions rich for type 1
and type 2a, but not type 2b. Embryonic myofibers were not observed
on the high responder, while the region of embryonic fibers on the
bottom panel was negative for dystrophin. Original magnification for
A = ×40; scale bar 500 μm. (PDF 233 kb)
Additional file 4: Residual PMO concentration by mouse and
muscle group. Residual morpholino concentration was measured in
diaphragm, heart, gastrocnemius, quadriceps, tibialis anterior, and triceps
muscle extracts at 30 days after PMO administration (n = 6). We observed
variable retention levels of PMO between muscle groups and animals
after 30 days of delivery. (PDF 119 kb)
Additional file 5: Dystrophin protein expression detected by IF and
WB after 7 days of PMO delivery. Four mice were treated with one
high dose of PMO (800 mg/kg) and sacrificed at 7 days. Tibialis anterior
muscles were dissected and analyzed by IF and WB. We observed low
levels of dystrophin protein by both quantification methods as compared
to saline-treated mice. (PDF 265 kb)
Additional file 6: Correlation between dystrophin transcript levels
by real-time qPCR and dystrophin protein amounts in TA muscle.
We compared dystrophin protein levels by IF and WB with mRNA
transcript levels at 30 days after one high-dose PMO injection (800 mg/
kg). A) By RTqPCR, mdx-3 mouse shows the highest percent exon skipping,
which translates to high dystrophin protein amounts as observed by B) WB
and C) IF. (PDF 158 kb)
Abbreviations
AOs: anti-sense oligonucleotides; DMD: Duchenne muscular dystrophy;
EDL: extensor digitorum longus; eMHC: embryonic myosin heavy chain;
IB: immunoblotting; IF: immunofluorescence; mRNA: messenger RNA;
MS: mass spectrometry; PMO or morpholino: phosphorodiamidate
morpholino oligomer; RSD: relative standard deviation; TA: tibialis anterior;
Gas: gastrocnemius; Dia: diaphragm.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MCV, MBK, SR, KU, KN, EPH, and JVA designed and supervised the study.
MCV, MBK, JSN, SR, KU, JFB, AAF, MWH, AZ, and CS performed experimental
work. KJB and YH performed mass spectrometry quantification of dystrophin
protein. UB and VS performed and analyzed PMO ELISA experiments. HGD
performed statistical analysis. MCV, MBK, SR, and KU performed primary data
analysis. MCV, MBK, KN, and EPH wrote the manuscript with significant input
from MWH, JSN, TAP, QLL, and JVA. All authors read and approved the final
manuscript.
Acknowledgements
K.N. is supported by the National Institutes of Health (5U54HD053177;
K26OD011171, P50AR060836-01), the Muscular Dystrophy Association, and
the US Department of Defense (W81XWH-05-1-0616, W81XWH-11-1-0782;
W81XWH-11-1-0330) and NICHD (P50AR060836-01 National Center for
Medical Rehabilitation Research). We thank Dr. Deborah McClellan for editorial
assistance.
Author details
1Research Center for Genetic Medicine, Children’s National Health System,
111 Michigan Avenue N.W., Washington, DC 20010, USA. 2Institute of
Biomedical Sciences, The George Washington University, Washington, DC,
USA. 3The John Walton Muscular Dystrophy Research Centre, MRC Centre for
Neuromuscular Diseases at Newcastle, Institute of Genetic Medicine,
Newcastle University, Newcastle upon Tyne, UK. 4McColl-Lockwood
Laboratory for Muscular Dystrophy Research, Neuromuscular/ALS Center,
Department of Neurology, Carolinas Medical Center, Charlotte, NC, USA.
5Center for Translational Science, Children’s National Health System,
Washington, DC, USA.
Received: 16 October 2015 Accepted: 24 November 2015
References
1. Hoffman EP. Genotype/phenotype correlations in Duchenne/Becker
dystrophy. Mol Cell Biol Hum Dis Serv 1993;3:12–36.
2. Hoffman EP, Monaco AP, Feener CC, Kunkel LM. Conservation of the
Duchenne muscular dystrophy gene in mice and humans. Science. 1987;
238(4825):347–50.
3. Hoffman EP, Schwartz L. Dystrophin and disease. Mol Aspects Med. 1991;
12(3):175–94.
4. Roses AD, Herbstreith MH, Appel SH. Membrane protein kinase alteration in
Duchenne muscular dystrophy. Nature. 1975;254(5498):350–1.
5. Hutter OF, Burton FL, Bovell DL. Mechanical properties of normal and mdx
mouse sarcolemma: bearing on function of dystrophin. J Muscle Res Cell
Motil. 1991;12(6):585–9.
6. Menke A, Jockusch H. Decreased osmotic stability of dystrophin-less muscle
cells from the mdx mouse. Nature. 1991;349(6304):69–71.
7. Menke A, Jockusch H. Extent of shock-induced membrane leakage in
human and mouse myotubes depends on dystrophin. J Cell Sci. 1995;108
(Pt 2):727–33.
8. Pasternak C, Wong S, Elson EL. Mechanical function of dystrophin in muscle
cells. J Cell Biol. 1995;128(3):355–61.
9. Emery AE. The muscular dystrophies. Lancet. 2002;359(9307):687–95.
Vila et al. Skeletal Muscle  (2015) 5:44 Page 11 of 12
10. Gilroy J, Cahalan JL, Berman R, Newman M. Cardiac and pulmonary
complications in Duchenne’s progressive muscular dystrophy. Circulation.
1963;27(4 Pt 1):484–93.
11. Melacini P, Vianello A, Villanova C, Fanin M, Miorin M, Angelini C, et al.
Cardiac and respiratory involvement in advanced stage Duchenne muscular
dystrophy. Neuromuscul Disord. 1996;6(5):367–76.
12. Manzur AY, Kinali M, Muntoni F. Update on the management of Duchenne
muscular dystrophy. Arch Dis Child. 2008;93(11):986–90.
13. Griggs RC, Herr BE, Reha A, Elfring G, Atkinson L, Cwik V, et al.
Corticosteroids in Duchenne muscular dystrophy: major variations in
practice. Muscle Nerve. 2013;48(1):27–31.
14. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al.
Diagnosis and management of Duchenne muscular dystrophy, part 2:
implementation of multidisciplinary care. Lancet Neurol. 2010;9(2):177–89.
15. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al.
Diagnosis and management of Duchenne muscular dystrophy, part 1:
diagnosis, and pharmacological and psychosocial management. Lancet
Neurol. 2010;9(1):77–93.
16. Wood MJ, Gait MJ, Yin H. RNA-targeted splice-correction therapy for
neuromuscular disease. Brain. 2010;133(Pt 4):957–72.
17. Lu QL, Rabinowitz A, Chen YC, Yokota T, Yin H, Alter J, et al. Systemic
delivery of antisense oligoribonucleotide restores dystrophin expression in
body-wide skeletal muscles. Proc Natl Acad Sci U S A. 2005;102(1):198–203.
18. Alter J, Lou F, Rabinowitz A, Yin H, Rosenfeld J, Wilton SD, et al. Systemic
delivery of morpholino oligonucleotide restores dystrophin expression
bodywide and improves dystrophic pathology. Nat Med. 2006;12(2):175–7.
19. Yokota T, Lu QL, Partridge T, Kobayashi M, Nakamura A, Takeda S, et al.
Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy
dogs. Ann Neurol. 2009;65(6):667–76.
20. Cirak S, Arechavala-Gomeza V, Guglieri M, Feng L, Torelli S, Anthony K, et al.
Exon skipping and dystrophin restoration in patients with Duchenne
muscular dystrophy after systemic phosphorodiamidate morpholino
oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet.
2011;378(9791):595–605.
21. Wu B, Lu P, Benrashid E, Malik S, Ashar J, Doran TJ, et al. Dose-dependent
restoration of dystrophin expression in cardiac muscle of dystrophic mice
by systemically delivered morpholino. Gene Ther. 2010;17(1):132–40.
22. Aoki Y, Nakamura A, Yokota T, Saito T, Okazawa H, Nagata T, et al. In-frame
dystrophin following exon 51-skipping improves muscle pathology and
function in the exon 52-deficient mdx mouse. Mol Ther. 2010;18(11):1995–2005.
23. Malerba A, Sharp PS, Graham IR, Arechavala-Gomeza V, Foster K, Muntoni F,
et al. Chronic systemic therapy with low-dose morpholino oligomers
ameliorates the pathology and normalizes locomotor behavior in mdx
mice. Mol Ther. 2011;19(2):345–54.
24. Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, Adkin C, et al. Local
restoration of dystrophin expression with the morpholino oligomer AVI-
4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled,
dose-escalation, proof-of-concept study. Lancet Neurol. 2009;8(10):918–28.
25. Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, et al.
Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol.
2013;74(5):637–47.
26. Goemans NM, Tulinius M, van den Akker JT, Burm BE, Ekhart PF,
Heuvelmans N, et al. Systemic administration of PRO051 in Duchenne’s
muscular dystrophy. N Engl J Med. 2011;364(16):1513–22.
27. Voit T, Topaloglu H, Straub V, Muntoni F, Deconinck N, Campion G, et al.
Safety and efficacy of drisapersen for the treatment of Duchenne muscular
dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled
phase 2 study. Lancet Neurol. 2014;13(10):987–96.
28. Yokota T, Pistilli E, Duddy W, Nagaraju K. Potential of oligonucleotide-
mediated exon-skipping therapy for Duchenne muscular dystrophy. Expert
Opin Biol Ther. 2007;7(6):831–42.
29. Sharp PS, Bye-a-Jee H, Wells DJ. Physiological characterization of muscle
strength with variable levels of dystrophin restoration in mdx mice
following local antisense therapy. Mol Ther. 2011;19(1):165–71.
30. Sazani P, Van Ness KP, Weller DL, Poage D, Nelson K, Shrewsbury SB.
Chemical and mechanistic toxicology evaluation of exon skipping
phosphorodiamidate morpholino oligomers in mdx mice. Int J Toxicol.
2011;30(3):322–33.
31. Hoffman EP, Bronson A, Levin AA, Takeda S, Yokota T, Baudy AR, et al.
Restoring dystrophin expression in Duchenne muscular dystrophy muscle
progress in exon skipping and stop codon read through. Am J Pathol. 2011;
179(1):12–22.
32. Hoffman EP, McNally EM. Exon-skipping therapy: a roadblock, detour, or
bump in the road. Sci Transl Med. 2014;6(230):230fs14.
33. Fiorillo AA, Heier CR, Novak JS, Tully CB, Brown KJ, Uaesoontrachoon K, et al.
TNF-alpha-Induced microRNAs control dystrophin expression in Becker
muscular dystrophy. Cell Rep. 2015;12:1678–90.
34. Baudy AR, Sali A, Jordan S, Kesari A, Johnston HK, Hoffman EP, et al. Non-
invasive optical imaging of muscle pathology in mdx mice using cathepsin
caged near-infrared imaging. Mol Imaging Biol. 2011;13(3):462–70.
35. Zhang A. The use of urinary and kidney SILAM proteomics to monitor
kidney response to high dose morpholino oligonucleotides in the mdx
mouse. Toxic Rep. 2015;2:838–49.
36. Spurney CF, Gordish-Dressman H, Guerron AD, Sali A, Pandey GS, Rawat R,
et al. Preclinical drug trials in the mdx mouse: assessment of reliable and
sensitive outcome measures. Muscle Nerve. 2009;39(5):591–602.
37. Kesari A, Fukuda M, Knoblach S, Bashir R, Nader GA, Rao D, et al. Dysferlin
deficiency shows compensatory induction of Rab27A/Slp2a that may
contribute to inflammatory onset. Am J Pathol. 2008;173(5):1476–87.
38. Goodman CA, Kotecki JA, Jacobs BL, Hornberger TA. Muscle fiber type-
dependent differences in the regulation of protein synthesis. PLoS ONE.
2012;7(5):e37890.
39. Brown KJ, Marathi R, Fiorillo AA, Ciccimaro EF, Sharma S, Rowlands DS et al.
Accurate quantitation of dystrophin protein in human skeletal muscle using
mass spectrometry. J Bioanal Biomed. 2012;Suppl 7.
40. Rayavarapu S, Coley W, Cakir E, Jahnke V, Takeda S, Aoki Y, et al.
Identification of disease specific pathways using in vivo SILAC proteomics in
dystrophin deficient mdx mouse. Mol Cell Proteomics. 2013;12(5):1061–73.
41. Sharma N, Medikayala S, Defour A, Rayavarapu S, Brown KJ, Hathout Y, et al.
Use of quantitative membrane proteomics identifies a novel role of
mitochondria in healing injured muscles. J Biol Chem. 2012;287(36):30455–67.
42. Burki U, Keane J, Blain A, O’Donovan L, Gait MJ, Laval SH, et al.
Development and application of an ultrasensitive hybridization-based ELISA
method for the determination of peptide-conjugated phosphorodiamidate
morpholino oligonucleotides. Nucleic Acid Ther. 2015;25:275–84.
43. Mittendorfer B, Andersen JL, Plomgaard P, Saltin B, Babraj JA, Smith K, et al.
Protein synthesis rates in human muscles: neither anatomical location nor
fibre-type composition are major determinants. J Physiol. 2005;563(Pt 1):
203–11.
44. Savary I, Debras E, Dardevet D, Sornet C, Capitan P, Prugnaud J, et al. Effect
of glucocorticoid excess on skeletal muscle and heart protein synthesis in
adult and old rats. Br J Nutr. 1998;79(3):297–304.
45. Dadgar S, Wang Z, Johnston H, Kesari A, Nagaraju K, Chen YW, et al.
Asynchronous remodeling is a driver of failed regeneration in Duchenne
muscular dystrophy. J Cell Biol. 2014;207(1):139–58.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Vila et al. Skeletal Muscle  (2015) 5:44 Page 12 of 12
